Shares of OrganiGram Holdings Inc. (NASDAQ:OGI) have been given an average rating of “Hold” by the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.21.
Several research firms have recently issued reports on OGI. CIBC cut their price target on OrganiGram from C$4.00 to C$3.50 and set a “neutral” rating for the company in a research note on Thursday, September 23rd. Atb Cap Markets reaffirmed a “sector perform” rating on shares of OrganiGram in a research note on Friday, July 23rd. Zacks Investment Research downgraded OrganiGram from a “hold” rating to a “sell” rating in a research note on Friday, September 3rd. Finally, Stifel Nicolaus cut their price target on OrganiGram from C$4.00 to C$3.75 and set a “hold” rating for the company in a research note on Thursday, July 15th.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Morgan Stanley grew its holdings in shares of OrganiGram by 59.0% during the 2nd quarter. Morgan Stanley now owns 841,936 shares of the company’s stock worth $2,407,000 after purchasing an additional 312,437 shares during the period. Advisor Resource Council purchased a new stake in shares of OrganiGram during the 2nd quarter worth about $34,000. Invesco Ltd. purchased a new stake in shares of OrganiGram during the 2nd quarter worth about $51,000. UBS Asset Management Americas Inc. grew its holdings in shares of OrganiGram by 9.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 171,000 shares of the company’s stock worth $490,000 after purchasing an additional 14,500 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of OrganiGram during the 2nd quarter worth about $62,000. Institutional investors own 13.76% of the company’s stock.
OrganiGram (NASDAQ:OGI) last released its earnings results on Monday, July 12th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. OrganiGram had a negative return on equity of 19.91% and a negative net margin of 190.24%. The company had revenue of $16.55 million during the quarter, compared to the consensus estimate of $13.95 million. As a group, equities analysts predict that OrganiGram will post -0.28 EPS for the current year.
OrganiGram Company Profile
Further Reading: Mutual funds are not immune from market timing
Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.